用于治疗乳腺癌的CXCR4向性致死诱导皮模仿剂
Abraham Akonnor1, Masaki Makise1, Akihiko Kuniyasu1
1Laboratory of Molecular Cell Pharmacology, Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan.
ACS omega
|July 17, 2023
概括
一种新型的CXCR4向皮相仿药,CTCE-KLAK,可以选择性地诱导三阴性乳腺癌细胞的亡. 这种药物在临床前模型中有效抑制瘤生长和转移,提供了一个有前途的新疗法策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物开发 药物开发
背景情况:
- 三阴性乳腺癌 (TNBC) 是具有不良结果的侵略性.
- CXCR4受体是乳腺癌的关键标.
- 对于TNBC,需要新的治疗策略.
研究的目的:
- 开发和评估一种针对CXCR4的皮多米米药,CTCE-KLAK,用于TNBC治疗.
- 评估CTCE-KLAK的体外和体外抗瘤活性.
- 阐明CTCE-KLAK诱导的细胞死亡机制.
主要方法:
- 开发CTCE-KLAK,这是CTCE-9908和KLAKLAK的融合.
- 在乳腺癌和正常细胞的体外细胞毒性测定.
- 使用4T1小鼠转移性乳腺癌模型的体内研究.
- 对细胞死亡途径的分析 (卡斯巴酶裂变,泛卡斯巴酶抑制).
主要成果:
- 在CTCE-KLAK检测中,TNBC细胞呈现选择性亡,而正常细胞则没有.
- 没有观察到酶激活,这表明非细胞死亡.
- 在体内,CTCE-KLAK显著抑制瘤生长和肺转移.
- 瘤选择性与受体介导的内部化有关.
结论:
- CTCE-KLAK是一种强效的,细胞选择性诱导性死亡症的诱导剂.
- 类药物显示出对TNBC的显著临床前疗效.
- CTCE-KLAK是TNBC的一个有希望的CXCR4向治疗候选药物.
更多相关视频
07:41A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
Published on: February 20, 2018
8.9K
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
204
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
204
Necrosis
4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
